Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02795819 · ClinicalTrials.gov registry record · Phase 1
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02795819 is a Phase 1 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 6 participants.
The verdict
NCT02795819, a Phase 1 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This phase 1 study was developed to identify recommended phase 2 doses (RP2Ds) of AR-42 and pazopanib when given in combination for subsequent clinical trials and may have potentially identified candidate pharmacodynamic and predictive biomarkers.
Interventions
- DRUG Pazopanib
- DRUG AR-42
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-07-08 |
| Est. Completion | 2019-03-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02795819
The ClinicalTrials.gov registry entry for NCT02795819 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pazopanib is the first listed.
NCT02795819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02795819 about?
NCT02795819 is a clinical study titled "Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer". This phase 1 study was developed to identify recommended phase 2 doses (RP2Ds) of AR-42 and pazopanib when given in combination for subsequent clinical trials and may have potentially identified candidate pharmacodynamic and predictive biomarkers.
What is the current status of trial NCT02795819?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2016-07-08. Estimated completion is 2019-03-14.
What interventions are being tested in trial NCT02795819?
The interventions under investigation include: Pazopanib (DRUG), AR-42 (DRUG).
Who is sponsoring clinical trial NCT02795819?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.